X
[{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$409.0 million","upfrontCash":"$32.0 million","newsHeadline":"Sosei Heptares and AbbVie Announce New Discovery Collaboration Targeting Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$409.0 million","upfrontCash":"$32.0 million","newsHeadline":"Sosei Heptares Receives $10 Million Milestone Payment in Discovery Collaboration with AbbVie Targeting Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Sosei Heptares and AbbVie entered into the discovery collaboration and option-to-license agreement to discover, develop and commercialize novel small molecule medicines that modulate GPCR targets of interest to AbbVie.
Lead Product(s):
Undisclosed
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
AbbVie Inc
Deal Size: $409.0 million
Upfront Cash: $32.0 million
Deal Type: Collaboration
December 13, 2022
Details:
Sosei Heptares will apply its proprietary StaR® technology and GPCR-focused Structure-based Drug Design (SBDD) capabilities and fund R&D activities through the completion of Investigational New Drug (IND)-enabling studies.
Lead Product(s):
Undisclosed
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
AbbVie Inc
Deal Size: $409.0 million
Upfront Cash: $32.0 million
Deal Type: Collaboration
June 25, 2020